Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
Dr. Shakardokht Jafari named 2024 Innovator of the Year at Dynamic Awards in Brighton's Grand Hotel.
TrueInvivo’s® DOSEmapper™ showcased at BRSS, ensuring precise gamma knife dosimetry and improved radiation safety.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TrueInvivo enhances cancer care with accurate, high-resolution in-vivo dosimetry system, optimizing radiotherapy outcomes.
